Fla. Hospital Wants Class Cert. In $867M Drug Antitrust Suit
A Florida hospital on Tuesday again requested certification of an $867 million antitrust class action accusing Astellas Pharma Inc. of improperly requiring use of its Adenoscan drug with patented cardiac tests,...To view the full article, register now.
Already a subscriber? Click here to view full article